teriparatide
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Osteoporosis
Conditions
Osteoporosis, Bone Loss, Spinal Cord Injury
Trial Timeline
Jun 1, 2009 → Dec 1, 2012
NCT ID
NCT00826228About teriparatide
teriparatide is a approved stage product being developed by Eli Lilly for Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00826228. Target conditions include Osteoporosis, Bone Loss, Spinal Cord Injury.
What happened to similar drugs?
20 of 20 similar drugs in Osteoporosis were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01705587 | Approved | Completed |
| NCT01360424 | Approved | Completed |
| NCT00826228 | Approved | Completed |
| NCT00696644 | Pre-clinical | Completed |
| NCT00535860 | Phase 2 | Completed |
| NCT00577863 | Phase 3 | Completed |
| NCT00557310 | Approved | Completed |
| NCT00259298 | Approved | Completed |
| NCT00191867 | Phase 2 | Completed |
| NCT00191321 | Phase 3 | Completed |
| NCT00532207 | Phase 3 | Completed |
| NCT00191893 | Phase 3 | Completed |
| NCT00191802 | Phase 3 | Completed |
| NCT00532545 | Approved | Completed |
Competing Products
20 competing products in Osteoporosis